PriceTargets.com logo

Vericel - VCEL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $61.14
  • Forecasted Upside: 4.66%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$58.42 As of 12/18/2024 01:39 PM ET
▲ +1.73 (3.05%)

This chart shows the closing price for VCEL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vericel Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VCEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VCEL

Analyst Price Target is $61.14
▲ +4.66% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Vericel in the last 3 months. The average price target is $61.14, with a high forecast of $67.00 and a low forecast of $57.00. The average price target represents a 4.66% upside from the last price of $58.42.

This chart shows the closing price for VCEL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Vericel. This rating has held steady since January 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/18/2024Truist FinancialBoost TargetBuy ➝ Buy$61.00 ➝ $67.00
12/2/2024StephensUpgradeStrong-Buy
11/26/2024BTIG ResearchBoost TargetBuy ➝ Buy$56.00 ➝ $66.00
11/19/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
8/27/2024TD CowenBoost TargetBuy ➝ Buy$55.00 ➝ $60.00
8/9/2024Canaccord Genuity GroupInitiated CoverageBuy$57.00
8/9/2024Canaccord Genuity GroupInitiated CoverageBuy$57.00
8/2/2024StephensBoost TargetOverweight ➝ Overweight$56.00 ➝ $58.00
8/2/2024HC WainwrightBoost TargetBuy ➝ Buy$55.00 ➝ $60.00
7/16/2024Truist FinancialBoost TargetBuy ➝ Buy$56.00 ➝ $57.00
7/15/2024BTIG ResearchLower TargetBuy ➝ Buy$56.00 ➝ $55.00
6/20/2024TD CowenInitiated CoverageBuy$55.00
5/9/2024HC WainwrightBoost TargetBuy ➝ Buy$53.00 ➝ $55.00
3/26/2024Truist FinancialReiterated RatingBuy ➝ Buy$54.00
3/1/2024Truist FinancialBoost TargetBuy ➝ Buy$51.00 ➝ $54.00
3/1/2024HC WainwrightBoost TargetBuy ➝ Buy$46.00 ➝ $53.00
1/25/2024Truist FinancialUpgradeHold ➝ Buy$39.00 ➝ $51.00
1/16/2024HC WainwrightBoost TargetBuy ➝ Buy$44.50 ➝ $46.00
11/9/2023Truist FinancialBoost TargetHold ➝ Hold$33.00 ➝ $39.00
10/16/2023Leerink PartnrsReiterated RatingOutperform
10/16/2023Leerink PartnersInitiated CoverageOutperform$42.00
9/21/2023Truist FinancialReiterated RatingHold ➝ Hold$39.00
9/21/2023StephensReiterated RatingOverweight ➝ Overweight$44.00
9/21/2023HC WainwrightBoost TargetBuy ➝ Buy$41.00 ➝ $44.50
8/8/2023BTIG ResearchUpgradeNeutral ➝ Buy$39.00
8/3/2023Truist FinancialLower TargetHold ➝ Hold$42.00 ➝ $39.00
8/3/2023HC WainwrightBoost TargetBuy ➝ Buy$37.00 ➝ $41.00
7/19/2023Truist FinancialBoost Target$36.00 ➝ $42.00
5/11/2023Truist FinancialBoost Target$31.00 ➝ $36.00
5/11/2023StephensBoost Target$39.00 ➝ $42.00
2/27/2023Truist FinancialBoost TargetHold$29.00 ➝ $31.00
1/31/2023Truist FinancialBoost TargetHold$25.00 ➝ $29.00
1/27/2023HC WainwrightReiterated RatingBuy$37.00
1/3/2023HC WainwrightBoost TargetBuy$35.00 ➝ $37.00
12/20/2022Truist FinancialBoost TargetHold$22.00 ➝ $25.00
11/15/2022Truist FinancialDowngradeHold
11/10/2022HC WainwrightLower TargetBuy$53.00 ➝ $35.00
11/9/2022BTIG ResearchDowngradeBuy ➝ Neutral
11/9/2022Truist FinancialDowngradeBuy ➝ Hold
10/13/2022StephensInitiated CoverageOverweight$40.00
7/22/2022Truist FinancialLower Target$33.00
7/18/2022BTIG ResearchLower TargetBuy$45.00 ➝ $34.00
2/25/2022Leerink PartnersBoost TargetOutperform$40.00 ➝ $45.00
12/21/2021Truist FinancialLower TargetBuy$55.00 ➝ $52.00
8/5/2021Leerink PartnersLower TargetOutperform$67.00 ➝ $62.00
6/30/2021OppenheimerReiterated RatingHold
5/6/2021HC WainwrightBoost TargetBuy$60.00 ➝ $65.00
2/25/2021HC WainwrightBoost TargetBuy$44.00 ➝ $60.00
2/25/2021Leerink PartnersBoost TargetOutperform$50.00 ➝ $60.00
2/22/2021BTIG ResearchBoost Target$45.00 ➝ $56.00
2/16/2021Truist FinancialBoost Target$40.00 ➝ $60.00
1/25/2021BTIG ResearchBoost TargetPositive ➝ Buy$37.00 ➝ $45.00
1/19/2021LADENBURG THALM/SH SHBoost TargetBuy$27.50 ➝ $44.00
1/12/2021HC WainwrightBoost TargetBuy$26.00 ➝ $44.00
1/11/2021OppenheimerDowngradeOutperform ➝ Market Perform
1/5/2021BTIG ResearchBoost TargetBuy$30.00 ➝ $37.00
12/17/2020StephensInitiated CoverageOverweight$31.00
10/19/2020BTIG ResearchBoost TargetBuy$23.00 ➝ $30.00
10/15/2020HC WainwrightBoost TargetBuy$22.00 ➝ $26.00
10/12/2020Leerink PartnersBoost TargetOutperform$20.00 ➝ $30.00
10/5/2020OppenheimerReiterated RatingBuy$32.00
9/23/2020BTIG ResearchBoost TargetBuy$21.00 ➝ $23.00
9/21/2020OppenheimerReiterated RatingBuy$32.00
9/17/2020Truist FinancialInitiated CoverageBuy$24.00 ➝ $24.00
9/9/2020BTIG ResearchReiterated RatingBuy$21.00
8/6/2020HC WainwrightReiterated RatingBuy$22.00
8/5/2020Needham & Company LLCInitiated CoverageHold
8/5/2020OppenheimerReiterated RatingBuy
7/9/2020BTIG ResearchReiterated RatingBuy$21.00
7/9/2020Needham & Company LLCReiterated RatingHold
5/6/2020HC WainwrightReiterated RatingBuy$22.00
5/6/2020LADENBURG THALM/SH SHBoost TargetBuy$20.00 ➝ $22.00
5/5/2020BTIG ResearchReiterated RatingBuy$21.00
5/5/2020Needham & Company LLCInitiated CoverageHold
5/5/2020OppenheimerReiterated RatingBuy$32.00
4/3/2020BTIG ResearchLower TargetBuy$24.00 ➝ $21.00
4/2/2020Needham & Company LLCReiterated RatingHold
2/26/2020BTIG ResearchReiterated RatingBuy$24.00
2/26/2020HC WainwrightReiterated RatingBuy
2/3/2020HC WainwrightBoost TargetBuy$21.00 ➝ $22.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

1.38 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 14 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/22/2024
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 21 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 12 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 14 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 8 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 18 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 28 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 28 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Vericel logo
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $58.42
Low: $56.05
High: $58.86

50 Day Range

MA: $50.84
Low: $40.09
High: $59.11

52 Week Range

Now: $58.42
Low: $32.31
High: $61.49

Volume

73,299 shs

Average Volume

424,058 shs

Market Capitalization

$2.88 billion

P/E Ratio

952.17

Dividend Yield

N/A

Beta

1.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Vericel?

The following Wall Street analysts have issued research reports on Vericel in the last year: BTIG Research, Canaccord Genuity Group Inc., HC Wainwright, Stephens, StockNews.com, TD Cowen, TheStreet, and Truist Financial Co..
View the latest analyst ratings for VCEL.

What is the current price target for Vericel?

0 Wall Street analysts have set twelve-month price targets for Vericel in the last year. Their average twelve-month price target is $61.14, suggesting a possible upside of 4.7%. Truist Financial Co. has the highest price target set, predicting VCEL will reach $67.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $57.00 for Vericel in the next year.
View the latest price targets for VCEL.

What is the current consensus analyst rating for Vericel?

Vericel currently has 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VCEL will outperform the market and that investors should add to their positions of Vericel.
View the latest ratings for VCEL.

What other companies compete with Vericel?

Other companies that are similar to Vericel include Qiagen, Intra-Cellular Therapies, Roivant Sciences, Ascendis Pharma A/S and Revolution Medicines. Learn More about companies similar to Vericel.

How do I contact Vericel's investor relations team?

Vericel's physical mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company's listed phone number is (617) 588-5555 and its investor relations email address is [email protected]. The official website for Vericel is www.vcel.com. Learn More about contacing Vericel investor relations.